Pravastatin use and cancer risk: a meta‐analysis of individual patient data from long‐term prospective controlled trials in Japan

Matsushita, Yasuyuki; Sugihara, Masahiro; Kaburagi, Junpei; Ozawa, Masumi; Iwashita, Mikio; Yoshida, Sanae; Saito, Hanako; Hattori, Yoko

doi:10.1002/pds.1870

Cited by 42 publications

(39 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found an association between statin use and reduced risk of certain B‐cell NHL subtypes (DLBCL and PCN). These findings are consistent with results from other studies . We previously reported a similar reduction of overall NHL risk associated with ever‐use of statins in a meta‐analysis of these studies .…”

Section: Discussionsupporting

confidence: 92%

“…These findings are consistent with results from other studies. [8][9][10][11][32][33][34] We previously reported a similar reduction of overall NHL risk associated with ever-use of statins in a meta-analysis of these studies. 15 Another study published later verified the inverse association between NHL risk and statin use (OR 5 0.52, 0.43-0.62).…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Associations between statin use and risk of non‐Hodgkin lymphomas by subtype

Zhang

Righolt

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Non-Hodgkin lymphomas (NHL) are a group of cancers with highly heterogeneous biology and clinical features. Statins are increasingly prescribed to prevent cardiovascular diseases. Early evidence shows a preventive effect of statins for some cancers, but their effect on NHL risk is unclear. We conducted a population-based nested case-control study involving 5,541 NHL cases and 27,315 controls matched for gender, age, place of residence and length of period of available prescription drug data. We assessed the use of statins prior to diagnosis (excluding the 12 months prior to the index date). We used conditional logistic regression models to estimate odds ratio (OR) and 95% confidence interval (CI) for use of any statin, adjusting for medical conditions, number of family physician visits for 5 years prior to index date, healthcare utilization, income and use of other medications. Over one-quarter of cases and controls were prescribed statins. Ever-use of any statin was associated with lower risk of Total NHL (OR = 0.82, 95% CI 0.76-0.89) and of certain subtypes including diffuse large B-cell lymphomas (DLBCL, OR = 0.77, 95% CI 0.65-0.92), plasma cell neoplasms (PCN, OR = 0.76, 95% CI 0.63-0.91) and other B-cell NHL (0.75, 0.59-0.95). Analysis by statin type suggested that the association was limited to high potency statin and lipophilic statin users. No clear duration or dose-response relationships were observed. Our findings provide evidence that statin use can reduce the risk of DLBCL and plasma cell lymphomas, but not other NHL types. Further studies are warranted to verify these associations and to examine the biological mechanisms.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 92%

Associations between statin use and risk of non‐Hodgkin lymphomas by subtype

Zhang

Righolt

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Sato et al (21) reported an observed/expected ratio of 0.63 (95%CI=0.01–3.49) in a pravastatin trial that included 179 participants in the statins arm, one of whom developed liver cancer. Matsushita et al (20), in a meta-analysis of three Japanese studies of pravastatin, reported a hazard ratio of 0.58 (0.18–1.84) based on 7 liver cancers in the control group and 5 liver cancers in the pravastatin group. Similarly, in a large meta-analysis of cancer outcomes in 27 trials (19), no relationship between statin use and liver cancer was identified (p=0.39), with 42 liver cancers reported in the statins arm and 51 in the control arm.…”

Section: Discussionmentioning

confidence: 99%

Statin use and risk of hepatocellular carcinoma in a U.S. population

McGlynn

Divine

Sahasrabuddhe

et al. 2014

Cancer Epidemiology

View full text Add to dashboard Cite

Purpose Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are medications widely prescribed to reduce cholesterol levels. Observational studies in high-risk populations, mostly in Asia, have suggested that statins are associated with a reduced risk of hepatocellular carcinoma (HCC). The current study sought to evaluate the association of statin use and HCC in a U.S.-based, low-risk, general population. Methods A nested case-control study was conducted among members of the Health Alliance Plan HMO of the Henry Ford Health System enrolled between 1999 and 2010. Electronic pharmacy records of statin use were compared among tumor registry-confirmed cases of HCC (n=94) and controls (n=468) matched on age, sex, diagnosis date, and length of HMO enrollment. Results In multivariate analyses, ever-use of statins was significantly inversely associated with development of HCC (Odds Ratio (OR):0.32, 95%CI: 0.15–0.67). No clear dose-response relationship was evident as statin use for ≤2 years (OR=0.32, 95%CI=0.13–0.83) and >2 years (OR=0.31, 95CI%=0.12–9.81) resulted in very similar ORs. Conclusions The use of statins among populations in low-risk HCC areas may be associated with decreased risk of HCC.

show abstract

“…33 The remaining meta-analyses reported null associations between statin use and breast cancer risk, even when stratified by statin type and study design. 6,29–32 …”

Section: Statins and Breast Cancer Preventionmentioning

confidence: 99%

Statins and breast cancer prognosis: evidence and opportunities

Ahern

Lash

Damkier

et al. 2014

The Lancet Oncology

167

141

View full text Add to dashboard Cite

SUMMARY Much preclinical and epidemiologic evidence supports anticancer effects of HMG-CoA reductase inhibitors (statins). Epidemiologic evidence does not support an association between statin use and reduced breast cancer incidence, but does support a protective effect of statins—particularly simvastatin—on breast cancer prognosis. We argue that the current evidence base is sufficient to justify a clinical trial of breast cancer adjuvant therapy with statins. We advocate for such a trial to be initiated without delay. If a protective effect of statins on breast cancer recurrence is supported by trial evidence, then the indications for a safe, well-tolerated, and in expensive treatment can be expanded to improve outcomes for breast cancer survivors. We discuss several design opportunities—including candidate predictive biomarkers of statin safety and efficacy—and offer solutions to key challenges to enrolment, follow-up, and analysis of such a trial.

show abstract

Pravastatin use and cancer risk: a meta‐analysis of individual patient data from long‐term prospective controlled trials in Japan

Abstract: Pravastatin did not increase the rate of cancer incidence or cancer death in a large population of Japanese patients followed for >70,000 patient-years.

Cited by 42 publications

References 35 publications

Associations between statin use and risk of non‐Hodgkin lymphomas by subtype

Associations between statin use and risk of non‐Hodgkin lymphomas by subtype

Statin use and risk of hepatocellular carcinoma in a U.S. population

Statins and breast cancer prognosis: evidence and opportunities

Contact Info

Product

Resources

About